Endonovo Therapeutics, Inc. engages in developing off bio-electronic approach to regenerative medicine. It focuses on rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. The company was founded on May 26, 2011 and is headquartered in Woodland Hills, CA.
Company profile
Ticker
ENDV
Exchange
Website
CEO
Alan Brian Collier
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Hanover Portfolio Acquisitions, Inc.
SEC CIK
ENDV stock data
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
21 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
8-K
Entry into a Material Definitive Agreement
27 Sep 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
10-Q
2022 Q1
Quarterly report
18 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
1-A/A
Offering $5M in Equity
10 May 22
10-K
2021 FY
Annual report
13 Apr 22
NT 10-K
Notice of late annual filing
31 Mar 22
Latest ownership filings
4
Alan Brian Collier
7 Jul 20
4
Alan Brian Collier
26 Feb 20
4/A
Alan Brian Collier
24 Jan 20
4/A
Alan Brian Collier
24 Jan 20
4
Alan Brian Collier
23 Jan 20
4
Alan Brian Collier
31 Dec 19
4
Alan Brian Collier
9 Dec 19
4
Alan Brian Collier
26 Nov 19
4
Alan Brian Collier
15 Nov 19
4
Alan Brian Collier
4 Nov 19
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 23.14 k | 23.14 k | 23.14 k | 23.14 k | 23.14 k | 23.14 k |
| Cash burn (monthly) | (no burn) | (no burn) | 201.12 k | 262.20 k | 41.29 k | 70.38 k |
| Cash used (since last report) | n/a | n/a | 840.11 k | 1.10 mm | 172.46 k | 294.00 k |
| Cash remaining | n/a | n/a | -816.97 k | -1.07 mm | -149.32 k | -270.86 k |
| Runway (months of cash) | n/a | n/a | -4.1 | -4.1 | -3.6 | -3.8 |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 1 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
Press releases
Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
31 Jan 23
Endonovo Partners with International Distributor for SofPulse® Line
26 Jan 23
New Details on Endonovo's Spin-Off of SofPulse, Inc.
19 Jan 23
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company
9 Jan 23
Endonovo Targets Dept. of Defense, VA & Federal Contracts
3 Jan 23